Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Revenue of Innoviva, Inc. (INVA)
Revenue in 2023 (TTM): $310.46 M
According to Innoviva, Inc.'s latest financial reports the company's current revenue (TTM) is $310.46 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Innoviva, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $310.46 M | $261.07 M | $248.96 M | $194.1 M | $179.72 M |
| 2022 | $331.34 M | $317.55 M | $322.25 M | $286.95 M | $213.92 M |
| 2021 | $391.87 M | $378.03 M | $478.18 M | $445.28 M | $368.84 M |
| 2020 | $336.79 M | $335.01 M | $386.42 M | $354.25 M | $224.4 M |
| 2019 | $261.02 M | $261.02 M | $265.43 M | $232.9 M | $157.29 M |
| 2018 | $261 M | $261 M | $248.08 M | $210.26 M | $395.06 M |
| 2017 | $217.22 M | $215.86 M | $191.86 M | $134.27 M | $134.14 M |
| 2016 | $133.57 M | $132.18 M | $125.91 M | $59.54 M | $59.54 M |
| 2015 | $53.95 M | $51.33 M | $46.98 M | $-18,760,000 | $-18,760,000 |
| 2014 | $8.43 M | $935 K | $-24,463,000 | $-73,530,000 | $-168,464,000 |
| 2013 | $4.76 M | $-4,280,000 | $-26,080,000 | $-170,701,000 | $-170,701,000 |
| 2012 | $135.76 M | $127.61 M | $-21,895,000 | $-18,542,000 | $-18,542,000 |
| 2011 | $24.51 M | $24.51 M | $-101,739,000 | $-115,344,000 | $-115,344,000 |
| 2010 | $24.22 M | $24.22 M | $-71,482,000 | $-83,862,000 | $-83,862,000 |
| 2009 | $24.37 M | $24.37 M | $-73,709,000 | $-85,302,000 | $-85,302,000 |
| 2008 | $23.1 M | $23.1 M | $-81,000,000 | $-98,623,000 | $-93,643,000 |
| 2007 | $22 M | $22 M | $-164,507,000 | $-159,997,000 | $-159,997,000 |
| 2006 | $19.59 M | $19.59 M | $-179,170,000 | $-166,044,000 | $-166,044,000 |
| 2005 | $12.05 M | $12.05 M | $-145,449,000 | $-143,164,000 | $-143,164,000 |
| 2004 | $8.94 M | $8.94 M | $-97,019,000 | $-102,654,000 | $-102,654,000 |
| 2003 | $3.61 M | $3.61 M | $-67,257,000 | $ | $-70,583,000 |
| 2002 | $156 K | $156 K | $-77,959,000 | $ | $-79,227,000 |
| 2001 | $ | $ | $-53,773,000 | $ | $-64,845,000 |
| 2000 | $ | $-43,188,000 | $-103,927,000 | $ | $-94,935,000 |